On 25 November 2020, Aktiespararna published their analysis of Follicum on their website. The analysis can also be read on Follicum’s webpage. Read the analysis at Aktiespararna.se For further information, please contact: Jan Alenfall – CEO, Follicum AB Telephone: +46 (0)709 31 51 15 Email: info@follicum.com About Follicum AB Follicum AB (Spotlight: FOLLI) develops drugs […]
Presentation BioStock Life Science Summit 2020, November 18
Our drug candidate FOL-005 has demonstrated increased hair growth on both healthy individuals and on patients with alopecia in two clinical phase II trials, which both demonstrated good safety and efficacy.
Read moreNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES,...
Follicum AB announced today that the patent which previously (June 22, 2020) received a so-called No...
Follicum AB today announced that all patients have been included in the company’s ongoing Phas...
On 25 November 2020, Aktiespararna published their analysis of Follicum on their website. The analys...
BioStock published an article on 2 November 2020 about Follicum, which can be read in full below. La...
BioStock published an article on 9 October 2020 about Follicum, which can be read in full below. Alo...
Follicum will attend the World Congress for Hair Research in Melbourne (WCHR), Australia, on 9-12 Ap...
